Tim Harris is Executive Vice President, Research and Development. Prior to joining Bioverativ, Tim was a venture partner at SV Life Sciences, a leading international life sciences venture capital firm, where he was responsible for identifying and analyzing investment opportunities for its two newest funds. Before that, Tim held the roles of Senior Vice President, Precision Medicine and Senior Vice President, Translational Medicine and Biochemistry at Biogen, where he was responsible for establishing foundational innovative technologies that advanced R&D efforts. Previously, Tim was Chief Technical Officer and Director of the Advanced Technology Program at SAIC-Frederick (now Leidos), which operates the Frederick National Laboratory, the National Cancer Institute’s leading center for cancer and AIDS research.  He has also served as President and Chief Executive Officer of SGX Pharmaceuticals (acquired by Eli Lilly) among other roles throughout his long career. He is currently on the Board of Directors of Opgen and is a visiting Professor at Columbia University. Tim is a molecular biologist and biochemist and has nearly 40 years of scientific and leadership expertise in the biotechnology industry. He holds a Ph. D in molecular virology and a D.Sc., both from the University of Birmingham, UK, and is credited with over 100 publications and five issued patents.  Tim Harris is Executive Vice President, Research and Development. Prior to joining Bioverativ, Tim was a venture partner at SV Life Sciences, a leading international life sciences venture capital firm, where he was responsible for identifying and analyzing investment opportunities for its two newest funds. Before that, Tim held the roles of Senior Vice President, Precision Medicine and Senior Vice President, Translational Medicine and Biochemistry at Biogen, where he was responsible for establishing foundational innovative technologies that advanced R&D efforts. Previously, Tim was Chief Technical Officer and Director of the Advanced Technology Program at SAIC-Frederick (now Leidos), which operates the Frederick National Laboratory, the National Cancer Institute’s leading center for cancer and AIDS research.  He has also served as President and Chief Executive Officer of SGX Pharmaceuticals (acquired by Eli Lilly) among other roles throughout his long career. He is currently on the Board of Directors of Opgen and is a visiting Professor at Columbia University. Tim is a molecular biologist and biochemist and has nearly 40 years of scientific and leadership expertise in the biotechnology industry. He holds a Ph. D in molecular virology and a D.Sc., both from the University of Birmingham, UK, and is credited with over 100 publications and five issued patents. 

Management